Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

This trial is testing a combination of two oral cancer drugs — chidamide (an epigenetic drug) and duvalisibon (a targeted therapy) — in people with a type of blood cancer called peripheral T-cell lymphoma (PTCL) or NK/T-cell lymphoma that has returned or stopped responding to prior chemotherapy. **You may be eligible if...** - You are 18–75 years old - You have been confirmed to have PTCL or NK/T-cell lymphoma by biopsy - Your lymphoma has relapsed (come back after remission) or is refractory (did not respond to at least one prior anthracycline-based chemotherapy regimen) - You have at least one measurable lymph node lesion greater than 1.5 cm - You have adequate blood counts and organ function **You may NOT be eligible if...** - Your lymphoma has spread to the brain or spinal fluid - You have received any prior PI3K inhibitor that your cancer progressed on - You have active HIV, active hepatitis B or C, or active CMV infection - You have had major surgery in the past 4 weeks - You are pregnant or breastfeeding - You have severe uncontrolled heart problems, recent stroke, or bleeding in the brain Talk to your doctor to see if this trial is right for you.